BioCentury
ARTICLE | Company News

Asana, Endo deal

June 16, 2014 7:00 AM UTC

Newco Asana acquired the early stage branded pharmaceutical discovery platform of Endo's Endo Pharmaceuticals Inc. subsidiary for an undisclosed upfront payment, plus milestones. The portfolio includes multiple preclinical compounds for cancer, pain and inflammation indications. The lead compound has IND-approval and is in development for prostate cancer, but the companies did not disclose a timeline for clinical testing. ...